Piramal Pharma receives EIR from USFDA for Turbhe facility

12 May 2025 Evaluate

Piramal Pharma has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Turbhe facility with VAI (Voluntary Action Indicated). Receipt of said EIR marks successful closure of the inspection.

Earlier, the USFDA had conducted General Good Manufacturing Practices (GMP) inspection at company’s Turbhe facility from February 11, 2025 to February 17, 2025.

Piramal Pharma provides end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.

Piramal Pharma Share Price

179.95 -0.60 (-0.33%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×